Sensitivity of PDX models to TKIs in vivo
| Sample ID . | Kinase alteration . | Agent . | Spleen weight (mg) . | P value (vs vehicle) . | Additional genetic alterations . |
|---|---|---|---|---|---|
| ALL1 | ETV6-ABL1 | Vehicle | 321.0 ± 18.0 | NA | |
| Das | 117.4 ± 16.2 | .0014 | |||
| ALL9 | RCSD1-ABL2 | Vehicle | 479.2 ± 17.80 | IKZF1 deletion, CDKN2A/B deletion | |
| Das | 136.5 ± 29.0 | <.0001 | |||
| ALL13 | SSBP2-CSF1R | Vehicle | 430.0 ± 40.2 | IKZF1 deletion, CDKN2A/B deletion | |
| Das | 156.2 ± 12.2 | .0001 | |||
| ALL14 | EBF1-PDGFRB | Vehicle | 290.8 ± 17.5 | EBF1 deletion | |
| Das | 109.3 ± 20.1 | .011 | |||
| Dex | 111.8 ± 18.1 | NS | |||
| Dex + das | 31.5 ± 8.2 | .0009 | |||
| ALL19 | PAX5-JAK2 | Vehicle | 289.3 ± 39.9 | IKZF1 deletion | |
| Ruxo | 122.2 ± 16.8 | .0089 | |||
| Dex | 21.3 ± 2.0 | .0019 | |||
| Dex + ruxo | 17.8 ± 1 | .0013 | |||
| ALL21 | ATF7IP-JAK2 | Vehicle | 636.4 ± 23.8 | IKZF1 deletion, CDKN2A/B deletion, BTLA-CD200 deletion | |
| Ruxo | 99.6 ± 9.2 | <.0001 | |||
| Dex | 34.6 ± 3.0 | <.0001 | |||
| Dex + ruxo | 17.0 ± 1.2 | <.0001 |
| Sample ID . | Kinase alteration . | Agent . | Spleen weight (mg) . | P value (vs vehicle) . | Additional genetic alterations . |
|---|---|---|---|---|---|
| ALL1 | ETV6-ABL1 | Vehicle | 321.0 ± 18.0 | NA | |
| Das | 117.4 ± 16.2 | .0014 | |||
| ALL9 | RCSD1-ABL2 | Vehicle | 479.2 ± 17.80 | IKZF1 deletion, CDKN2A/B deletion | |
| Das | 136.5 ± 29.0 | <.0001 | |||
| ALL13 | SSBP2-CSF1R | Vehicle | 430.0 ± 40.2 | IKZF1 deletion, CDKN2A/B deletion | |
| Das | 156.2 ± 12.2 | .0001 | |||
| ALL14 | EBF1-PDGFRB | Vehicle | 290.8 ± 17.5 | EBF1 deletion | |
| Das | 109.3 ± 20.1 | .011 | |||
| Dex | 111.8 ± 18.1 | NS | |||
| Dex + das | 31.5 ± 8.2 | .0009 | |||
| ALL19 | PAX5-JAK2 | Vehicle | 289.3 ± 39.9 | IKZF1 deletion | |
| Ruxo | 122.2 ± 16.8 | .0089 | |||
| Dex | 21.3 ± 2.0 | .0019 | |||
| Dex + ruxo | 17.8 ± 1 | .0013 | |||
| ALL21 | ATF7IP-JAK2 | Vehicle | 636.4 ± 23.8 | IKZF1 deletion, CDKN2A/B deletion, BTLA-CD200 deletion | |
| Ruxo | 99.6 ± 9.2 | <.0001 | |||
| Dex | 34.6 ± 3.0 | <.0001 | |||
| Dex + ruxo | 17.0 ± 1.2 | <.0001 |
Spleen weight measured by mean ± SD (n = 5). P value calculated for analysis of slope by linear regression and unpaired 2-way t test comparing vehicle with dasatinib (ALL1, ALL9, ALL13), or 1-way ANOVA with Tukey posttest for multiple comparisons (ALL14, ALL19, ALL21). Additional genetic alterations determined by single nucleotide polymorphism profiling for recurrent copy number alterations in ALL.
Das, dasatinib; Dex, dexamethasone; NA, not available; NS, not significant; Ruxo, ruxolitinib.